Response to medical treatment in patients with Crohn's disease: The role of NOD2/CRAD15, disease phenotype, and age of diagnosis

Digestive Diseases and Sciences

Volumn 55, Issue 6, 2010, Pages 1674-1680

  Weiss, B ^a,b   Lebowitz, O ^a,b   Fidder, H H ^a,b   Maza, I ^c,d   Levine, A ^b,e   Shaoul, R ^d,f   Reif, S ^b,g   Bujanover, Y ^a,b   Karban, A ^c,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f BNAI ZION MEDICAL CENTER   (Israel)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Medical treatment; NOD2 CARD15; Response

Indexed keywords

AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; INFLIXIMAB; MERCAPTOPURINE; STEROID;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SMALL INTESTINE DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISRAEL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954426066     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0936-8     Document Type: Article

References (30)

1. JP Vader F Froehlich P Juillerat B Burnand C Felley J-J Gonvers C Mottet V Pittet RW Dubois V Wietlisbach P Michetti 2006 Appropriate treatment for Cohn's disease: Methodology and summary results of a multidisciplinary international expert panel approach-EPACT Digestion 73 237 248 10.1159/000095505 16940727 (Pubitemid 44448885)
2. Travis SPL, Stange EF, Lémann M, Öresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel J-F, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(Suppl 1):i16-i35. (Pubitemid 43268291)
3. JC Escher A Jan JM Taminiau E Edward S Nieuwenhuis HA Büller RJ Grand 2003 Treatment of inflammatory bowel disease in childhood: Best available evidence Inflamm Bowel Dis 9 34 58 10.1097/00054725-200301000-00006 12656136 (Pubitemid 36124247)
4. P Munkholm E Langholz M Davidsen V Binder 1994 Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 35 360 362 10.1136/gut.35.3.360 1:STN:280:DyaK2c3gtVKlsQ%3D%3D 8150347 (Pubitemid 24092906)
5. WA Faubion Jr EV Loftus Jr WS Harmsen AR Zinsmeister WJ Sandborn 2001 The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study Gastroeneterolgy 121 255 260 10.1053/gast.2001.26279 1:CAS:528:DC%2BD3MXmsVymsrY%3D (Pubitemid 32729372)
6. W Reinish H Volgelsang 2002 Steroid dependency in Crohn's disease Gastroenterolgy 123 393 394 10.1053/gast.2002.34592
7. J Markowitz J Hyams D Mack N LeLeiko J Evans S Kugathasan M Pfefferkorn A Mezoff J Rosh V Tolia A Otley A Griffiths MS Moyer M Oliva-Hemker R Wyllie R Rothbaum A Bousvaros JF Del Rosario S Hale T Lerer IBD Pediatric Collaborative Research Group 2006 Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn's disease Clin Gastroentrol Hepatol 4 1124 1129 10.1016/j.cgh.2006.05.011 1:CAS:528: DC%2BD28XhtVOrurjM (Pubitemid 44311642)
8. A Teml E Schaeffeler KR Herrlinger U Klotz M Schwab 2007 Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing Clin Pharmacokinet 46 187 208 10.2165/00003088-200746030-00001 1:CAS:528:DC%2BD2sXltFWlsLc%3D 17328579 (Pubitemid 46425646)
9. J Hyams W Crandall S Kugathasan A Griffiths A Olson J Johanns G Liu S Travers R Heuschkel J Markowitz S Cohen H Winter G Veereman-Wauters G Ferry R Baldassano 2007 Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children Gastroenterology 132 863 873 10.1053/j.gastro.2006.12.003 1:CAS:528:DC%2BD2sXkslCjtbc%3D 17324398 (Pubitemid 46454266)
10. SB Hanauer PG Feagan GR Lichtenstein LF Mayer S Schreiber JF Colombel D Rachmilewitz DC Wolf A Olson W Bao P Rutgeerts The ACCENT I Study Group 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial Lancet 359 9317 1541 1549 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D 12047962 (Pubitemid 34621118)
11. M Kappelman A Bousvaros J Hyams J Markowitz M Pfefferkorn S Kugathasan J Rosh A Otley D Mack A Griffiths J Evans RJ Grand C Langton K Kleinman JA Finkelstein 2007 Intercenter variation in initial management of children with Crohn's disease Inflamm Bowel Dis 13 890 895 10.1002/ibd.20121 17286275 (Pubitemid 47203867)
12. B Weiss R Shamir Y Bujanover M Watterman C Hartman A Fradkin D Berkowitz I Weintraub R Eliakim A Karban 2004 NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared to adults with Crohn's disease J Pediatr 145 208 212 10.1016/j.jpeds.2004.05.024 1:CAS:528:DC%2BD2cXmt1Chsb0%3D 15289769 (Pubitemid 38993393)
13. A Karban M Waterman CT Panhuysen RD Pollak S Nesher L Datta B Weiss A Suissa R Shamir SR Brant R Eliakim 2004 NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic jews with Crohn's disease Am J Gastroenterol 99 1134 1140 10.1111/j.1572-0241.2004.04156.x 15180737 (Pubitemid 38917820)
14. HH Fidder S Olschwang B Avidan H Zouali A Lang E Bardan O Picard S Bar-Meir JF Colombel Y Chowers 2003 Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients Am J Med Genet 121A 240 244 10.1002/ajmg.a.20209 12923865 (Pubitemid 37107758)
15. MS Silverberg J Satsangi T Ahmad, et al. 2005 Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology Can J Gastroenterol 19 Suppl A 5 36 16151544
16. RF Harvey JM Bradshaw 1980 A simple index of Crohn's disease activity Lancet 1 514 10.1016/S0140-6736(80)92767-1 1:STN:280:DyaL3c7kt1Wjtg%3D%3D 6102236
17. D Walkiewicz SL Werlin D Fish M Scanlon P Hanaway S Kugathasan 2008 Fecal calprotectin is useful in predicting disease relapse in pediatrix inflammatory bowel disease Inflamm Bowel Dis 14 669 673 10.1002/ibd.20376 18240279 (Pubitemid 351742984)
18. TR Walker ML Land A Kartashov TM Saslowsky DM Lyerly JH Boone PA Rufo 2007 Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease J Pediatr Gastroenterol Nutr 44 414 422 10.1097/MPG.0b013e3180308d8e 1:CAS:528: DC%2BD2sXjvVKitb8%3D 17414136 (Pubitemid 46573222)
19. Dixon WJ. BMDP statistical software. Los-Angeles: University of California Press, 1993.
20. S Cucchiara A Latiano O Palmieri RB Canani Renata S D'Inca G Guariso G Vieni D De Venuto G Riegler GL DeAngelis D Guagnozzi C Bascietto E Miele MR Valvano F Bossa V Annese 2007 on behalf of the Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease J Pediatr Gastroenterol Nutr 44 171 179 10.1097/MPG. 0b013e31802c41f3 1:CAS:528:DC%2BD2sXptFegsg%3D%3D 17255827 (Pubitemid 46175068)
21. R Towers T Naftali G Gabay M Carlebach A Klein B Novis 2005 High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance Clin Exp Immunol 141 357 362 10.1111/j.1365-2249.2005.02846.x 1:CAS:528:DC%2BD2MXotFakuro%3D 15996200 (Pubitemid 41003360)
22. MC Dubinski Y Huiying PV Hassard EG Seidman LY Kam MT Abreu SR Targan EA Vasiliauskas 2002 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 904 915 10.1053/gast.2002.32420
23. I Tiede G Fritz S Strans D Poppe R Dvorsky D Strand HA Lehr S Wirtz C Becker R Atreya J Mudter K Hildner B Bartsch M Holtmann R Blumberg H Walczak H Iven PR Galle MR Ahmadian MF Neurath 2003 CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 1133 1145 1:CAS:528:DC%2BD3sXjtFCrsrY%3D 12697733 (Pubitemid 36519931)
24. S Vermeire E Louis P Rutgeerts M De Vos A Van Gossum J Belaiche P Pescatore R Fiasse P Pelckmans R Vlietinck F Merlin H Zouali G Thomas JF Colombel JP Hugot 2002 NOD2/CARD15 does not influence response to infliximab in Crohn's disease Gastroenterology 123 106 111 10.1053/gast.2002.34172 1:CAS:528:DC%2BD38Xmt1aiu7s%3D 12105838 (Pubitemid 34747530)
25. E Urcelay JL Mendoza A Martinez L Fernandez C Taxonera M Diaz-Rubio EG de la Concha 2005 IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab World J Gastroenterol 11 1187 1192 1:CAS:528:DC%2BD2MXjt1ygu7g%3D 15754402 (Pubitemid 40353007)
26. H Matsukura S Ikeda N Yoshimura M Takazoe M Muramatsu 2008 Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRCF1B) affect responses to infliximab in Crohn's disease patients in Japan Aliment Pharmacol Ther 27 765 770 1:CAS:528:DC%2BD1cXlvVGqu70%3D 18248655 (Pubitemid 351490066)
27. WJ Sandborn BG Feagan GR Lichtenstein 2007 Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission Aliment Pharmacol Ther 26 987 1003 10.1111/j.1365-2036. 2007.03361.x 1:CAS:528:DC%2BD2sXht1SmtrbI 17877506 (Pubitemid 46985493)
28. DP Franchimont E Louis F Croes, et al. 1998 Clinical pattern of corticoid dependent Crohn's disease Eur J Gastroenterol Hepatol 10 821 825 10.1097/00042737-199810000-00001 1:STN:280:DyaK1M%2FkslaqtA%3D%3D 9831401 (Pubitemid 28493255)
29. JM Polito B Childs ED Mellits AZ Tokayer ML Harris TM Bayless 1996 Crohn's disease: Influence of age at diagnosis on site and clinical type of disease Gastroenterology 111 580 586 10.1053/gast.1996.v111.pm8780560 8780560 (Pubitemid 26293220)
30. R Heuschkel C Salvestrini RM Beattie H Hildebrand T Walters A Griffiths 2008 Guidelines for the management of growth failure in childhood inflammatory bowel disease Inflamm Bowel Dis 14 839 849 10.1002/ibd.20378 18266237 (Pubitemid 351898069)